Samsung Biologics announced on Monday that it received the Sustainability Leadership award at the CDMO Leadership Awards. This achievement cements Samsung Biologics’ position as a global leader in sustainable management and marks an unprecedented 13-year winning streak for a South Korean company.
The CDMO Leadership Awards is a prestigious global event jointly organized by Outsourced Pharma, a research institute in the pharmaceutical and biotech sectors, and Life Science Connect, a leading life sciences publication.
Award categories are segmented by portfolio, encompassing biopharmaceuticals, cell and gene therapies, and more. This year, the evaluation process was refined to categorize companies as large or small based on revenue, enabling more accurate comparisons between similarly sized firms.
Samsung Biologics clinched the Sustainability Leadership award from the judging panel this year, earning recognition for its commitment to implementing sustainable production processes and reducing environmental impact.
In 2022, Samsung Biologics made significant strides in sustainability by announcing its Net Zero by 2050 pledge and joining the RE100 initiative. The company has also taken a leading role in global sustainable management, chairing the supply chain sector in the Sustainable Markets Initiative, spearheaded by the British royal family.
Furthermore, Samsung Biologics was honored with the Best in Class award in the Cultural Fit category among large biopharmaceutical CDMO companies. This accolade underscores the company’s value as an ideal partner, known for its responsive customer service and effective communication.
To meet growing global demand, Samsung Biologics is pursuing a comprehensive investment strategy. This includes expanding production capacity and acquiring next-generation modality technologies, all aimed at enhancing its customer-centric CDMO competitiveness and accelerating its ascent to becoming a top-tier global biotech company.
In the contract manufacturing (CMO) sector, the company has significantly boosted its global production capacity to 845,000 liters. This expansion was achieved through the full-scale operation of its fifth plant and the strategic acquisition of the Rockville facility in the United States, securing Samsung Biologics’ position as the world’s largest biomanufacturing powerhouse.
On the contract development (CDO) front, Samsung Biologics has committed to a substantial investment of about $5.25 billion in its third biocampus, acquired last November. The company is also bolstering its CDO portfolio by bringing master cell bank (MCB) production and vector manufacturing services in-house.
John Lim, CEO of Samsung Biologics, said the award reflects clients’ continued trust and the company’s ongoing efforts to implement sustainable practices across its operations, adding that Samsung Biologics will remain focused on advancing sustainable innovation by delivering high-quality pharmaceuticals on schedule and strengthening collaboration with global partners.